Coopervision’s MiSight 1-day contact lens has been awarded the 2020 Popular Science: Best of What’s New Award in the health category.
The US’ Popular Science award recognises up to 100 of the most innovative technologies from the past year across 10 categories, including health, home, aerospace and security, with each product or technology representing a significant step forward in its category.
“MiSight 1-day is the only FDA-approved treatment that can help reduce the severity of myopia progression and we are delighted that Popular Science has recognised the impact of this technology,” said Joe Tanner, Coopervision’s ANZ professional services manager.
Announcing the win, Coopervision also unveiled new data from its MiSight clinical trial revealing that nearly one-in-four children’s eyes originally fitted with MiSight 1-day remain stable at their initial myopia level after six years.
For more, see https://eyeonoptics.co.nz/articles/archive/misight-six-year-results/
